> 71 Tratamiento sistémico del cáncer de mama BIBLIOGRAFÍA RECOMENDADA – Jackish C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the Hanna Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019; Apr 18:e190339. – Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012. Apr 18;(4):CD006243. – Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017;26(4):632. – Piccart M. Oral presentation SABCS 2019. Available from: https://www.sabcs.org/2019-SABCS-sup-sup- /2019-SABCS-Overview – Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al.; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617. Epub 2018 Dec 5. – Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. APHINITY Steering Committee and Investigators Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122. Figura 1. Propuesta de algoritmo de manejo del cáncer de mama HER2+ estadios iniciales si T > 2 y/o afectación ganglionar. Neoadyuvancia Pertuzumab Trastuzumab Quimioterapia Adyuvancia Trastuzumab 1 año Pertuzumab 1 año en N+ al diagnóstico Adyuvancia TDM1 14 cilcos Cirugía *RCp: respuesta completa patológica. Enfermedad residual RCp*
RkJQdWJsaXNoZXIy MTQzMjMwMg==